Comparative Pharmacology
Head-to-head clinical analysis: BRIMONIDINE TARTRATE TIMOLOL MALEATE versus LABETALOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIMONIDINE TARTRATE TIMOLOL MALEATE versus LABETALOL HYDROCHLORIDE.
BRIMONIDINE TARTRATE; TIMOLOL MALEATE vs LABETALOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brimonidine is a selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Timolol is a non-selective beta-adrenergic receptor blocker that decreases aqueous humor production by inhibiting beta-2 receptors in the ciliary epithelium.
Labetalol is a non-selective beta-adrenoceptor blocker and selective alpha-1 adrenoceptor blocker. It reduces myocardial contractility, heart rate, and peripheral vascular resistance.
One drop of the fixed combination (0.2% brimonidine/0.5% timolol) in the affected eye(s) twice daily, approximately 12 hours apart.
Oral: Initial 100 mg twice daily, titrate up to 200-400 mg twice daily; maximum 2400 mg/day. IV: 20 mg slow IV over 2 minutes, then 40-80 mg every 10 minutes as needed up to 300 mg total; or continuous IV infusion at 0.5-2 mg/min.
None Documented
None Documented
Brimonidine: ~3 hours (terminal); timolol: ~4–6 hours (terminal). Clinical context: allows twice-daily dosing for brimonidine/timolol combination.
Terminal elimination half-life: 6-8 hours. In renal impairment, half-life may be slightly prolonged but not clinically significant; in hepatic impairment, half-life may be significantly prolonged.
Brimonidine: primarily renal (74% as unchanged drug); timolol: renal (20% unchanged, remainder as metabolites) and fecal (small amount).
Primarily hepatic metabolism; ~5% excreted unchanged in urine; ~55-60% as glucuronide conjugates in urine; fecal excretion <5%.
Category A/B
Category A/B
Beta-Blocker
Alpha/Beta-Blocker